MATTHEW HAGEMEYER: Open Payments
NPI 1720209380 · OGDEN, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$407 in 28 payments from 9 companies in 2025. Trend: 2023 $369 · 2024 $415 · 2025 $407
Food & beverage: $407
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $154 |
| PFIZER INC. | 4 | $86 |
| GlaxoSmithKline, LLC. | 2 | $37 |
| Astellas Pharma US Inc | 1 | $34 |
| Gilead Sciences, Inc. | 2 | $31 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $16 |
| Organon LLC | 2 | $15 |
Products named: VRAYLAR, NURTEC ODT, UBRELVY, Veozah, QULIPTA, SHINGRIX, BREZTRI, TRELEGY ELLIPTA.
Industry payments across UT — which companies pay providers there.
